Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA.

Area of Science:

• Immunology
• Endocrinology
• Clinical Diagnostics

Background:

• Type 1 diabetes (T1D) screening requires sensitive and specific insulin autoantibody (IAA) assays for multi-laboratory use.
• Current IAA assays face challenges in sensitivity, specificity, and scalability for global screening initiatives.

Purpose of the Study:

• To develop and validate a novel ELISA-based platform for detecting insulin autoantibodies (IAA).
• To assess the assay's performance in identifying individuals at risk for T1D.

Main Methods:

• Development of a new bridging ELISA for IAA detection.
• Validation of the assay in diverse cohorts: stage 3 T1D patients, children with islet autoantibodies, and antibody-negative control children.

Main Results:

• The bridging ELISA-IAA assay demonstrated excellent sensitivity and specificity.
• The assay effectively identified high-risk individuals for T1D.
• The assay proved to be a practical and scalable solution.

Conclusions:

• The novel bridging ELISA-IAA assay is a reliable tool for T1D population screening.
• This assay facilitates accurate clinical diagnosis of T1D across multiple laboratories.
• The developed platform supports global efforts in T1D early detection and management.